First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.

Trial Profile

First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs OBT 357 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man
  • Acronyms ARMY
  • Sponsors Menarini
  • Most Recent Events

    • 25 Nov 2016 Status changed from active, no longer recruiting to recruiting.
    • 25 Nov 2016 Planned End Date changed from 1 Jun 2017 to 1 Sep 2018.
    • 25 Nov 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top